Designed by
patients for patients

Clarify Medical was founded by a psoriasis patient, Martyn Gross, who had excellent results with UVB therapy but found it very difficult to receive in-office treatment three times a week. His concept of a mobile, easy-to-use home UVB system, linked with the patient's physician, inspired years of research and development with hundreds of psoriasis and vitiligo patients and their physicians. Patients designed the integrated technology and service solution we offer today.

The Clarify Management Team

Our team of physicians, engineers, software experts, patient advisors and scientists are dedicated to creating new products and services that support patients and the clinicians who care for them.

Clarify. Life in a New Light.

George Mahaffey

President & CEO

Mr. Mahaffey is the President and CEO of Clarify Medical, and has over 30 years of pharmaceutical and biotechnology industry experience. In March 2011 he was named President and CEO of Lithera, Inc., later renamed Neothetics, a clinical stage special pharmaceutical aesthetics company.  While there he successfully completed an IPO in November 2014.  He previously served as CEO of Peplin, Inc. after the dermatology company was acquired by LEO Pharma A/S in 2009, where he played an instrumental role in the transaction. Prior to the acquisition, he served as Peplin’s Chief Commercial Officer and VP, Sales and Marketing. Mr. Mahaffey also served as Sr. VP, Sales and Marketing for Cotherix, Inc. where he led the corporate commercialization and successful launch of Ventavis® (iloprost), an orphan drug to treat Pulmonary Arterial Hypertension. He was heavily involved in the acquisition of CoTherix by Actelion Ltd. in 2007. Prior to CoTherix, Mr. Mahaffey worked at Scios, Inc. (acquired by Johnson & Johnson in 2003) where he led the launch of Natrecor® (nesiritide) to treat acutely decompensated congestive heart failure. Mr. Mahaffey also worked in various marketing functions at Neurex, Inc. (acquired by Elan Corp. in 1998). He began his pharmaceutical career at DuPont Pharmaceuticals where he held various sales and marketing positions. Mr. Mahaffey has a Chemical Engineering degree from the University of Delaware and an MBA from the University of South Florida.

Don Canal

Don Canal has over 25 years of experience in the medical device industry serving in senior management positions in Design & Development, and Quality and Regulatory Affairs with startup companies such as CardioNet, Tandem Diabetes Care and most recently, Ivera Medical which was sold to 3M in March 2015. He has also served as VP GM for leading contract medical device design, research and development and manufacturing services.

Wael Ahwal

Wael has 16 years of experience in the medical device and the diagnostic industry, holding senior positions in Design & Development, Software Validation and Verification, and Quality. Wael started his career at L3 Communication, moved to Gen-Probe, where he joined the Software Validation and Verification team as a lead. Most recently he served as Director of Quality Systems at Sotera Wireless.

Teddy Fulham

Prior to joining Clarify, Teddy was responsible for Strategy and Product Management at Sotera Wireless, and before that was a Market Manager for Pyxis Medication Management Technologies, owned by Becton Dickinson. Earlier, he held roles in corporate finance & accounting as well as business unit financial planning and analysis at CareFusion.

Andre Gamelin

Andre Gamelin is a medical technology innovator with extensive experience leading the development of electro-mechanical and electro-optical products.  Andre joined Clarify Medical at the beginning, where he studied the needs of patients and physicians, and architected a technology driven system to provide precision home phototherapy to patients with chronic skin conditions. Andre is a named inventor on the core Clarify patents protecting the smart-phone connected system and the precision lighting engine.

Prior to leading product development at Clarify Medical, Andre held leadership positions at Becton-Dickinson (CareFusion) developing critical infusion pumps, at Masimo Corporation developing non-invasive blood gas sensors using LED technology, and at Inovio Biomedical developing electroporation devices for cancer & DNA therapies. Andre co-founded Allegrotek, a product development and contract manufacturing company and also developed a real-time blood gas analyzer at Medtronic (Puritan-Bennett). Andre holds a BS degree in electrical engineering from UCSD.

The Clarify Board of Directors

David F. Hale

Mr. Hale serves as Chairman of the Board of Clarify Medical, Inc. He is Chairman and CEO of Hale Biopharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. He was involved in the formation and development of SkinMedica, an aesthetic skincare company, and served as Executive Chairman and Chairman from 2001 through that company’s sale to Allergan for $315 million.

Mr. Hale served as Chairman of Santarus, Inc. prior to its sale to Salix Pharmaceuticals in 2014, Micromet prior to its sale to Amgen in 2012 for $1.2 billion, Somaxon Pharmaceuticals prior to its sale to Permix in 2013, and Crisi Medical Systems prior to its sale to Becton Dickinson & Co. in 2015.    

Mr. Hale is a serial entrepreneur who has been involved in the formation and/or development of many other life sciences companies. In addition to the companies above, these include Hybritech, Viagene, Gensia Sicor, CancerVax, Neurelis, MDRejuvena, Dermata, Adgica Health, Oncternal, Agility Clinical, Biocept, Neurana and Colorescience, Inc. He serves on the board of two public companies, Conatus and BIOCEPT.

James M. Sweeney

Mr. Sweeney was the founder, Chairman and CEO of Home Health Care of America, later Caremark, which pioneered the home IV therapy industry and was sold to Baxter International for $528 million, and eventually to CVS for $24 billion. In 2014 CVS also purchased Coram Healthcare, an industry rollup Mr. Sweeney also founded, for $2.4 billion. Mr. Sweeney also led the successful LBO, turnaround and IPO of McGaw Inc, part of B. Braun Medical. Initial investors in McGaw received a sixfold increase in value in three and one half years, with a 77%  IRR.

Subsequently, he founded and served as Chairman and CEO of CardioNet, now BioTelemetry (NASDAQ: BEAT), a wireless healthcare company that introduced Mobile Cardiac Outpatient Telemetry, a life saving technology and service for detecting and diagnosing episodic arrhythmias. Its market capitalization is currently $1 billion.

Amit Pandya, MD

Dr. Pandya, a board certified dermatologist, is also a professor in the Department of Dermatology at the University of Texas Southwest Medical Center. He is a recipient of the Arnold P. Gold Foundation Humanism in Medicine Award from the American Academy of Dermatology and the University of Texas Regents’ Outstanding Teaching Award.

Dr. Pandya has also served as Clinical Director of the General Dermatology Clinic and Director of the Pharmaceutical Studies Unit at the University Medical Center and was elected by peers for inclusion in “Best Doctors in America” for many years. He has served as dermatological team leader and volunteer in many medical mission trips to Mexico and India and regularly serves as a volunteer dermatologist in clinics and disease screening projects in the United States.

Dr. Pandya is recognized as an international authority on pigmentary disorders, and is an author of over 117 peer reviewed publications and 45 book chapters and other publications on dermatologic disorders, as well as abstracts and articles. Dr. Pandya has also managed home phototherapy for hundreds of patients. Dr. Pandya’s expertise will be invaluable to Clarify in serving vitiligo patients and the physicians who treat them. An estimated 3 million individuals in the US alone have vitiligo and more than 60 million people worldwide are believed to suffer from the disease. Phototherapy delivered in combination with topical treatments is the gold standard of care for vitiligo patients; early intervention is key to success in re-pigmentation.

Rex Bright

Mr. Rex Bright is a specialty pharmaceuticals and biotech executive with extensive experience in dermatology. Mr. Bright spent 19 years with Johnson & Johnson where he headed the dermatology business until joining Allergan in 1983. At Allergan, he founded their skincare business and served as president before becoming a startup and turnaround CEO. He has served as President & CEO of several successful pharmaceutical and biotechnology companies.

Mr. Bright co-founded SkinMedica in 2002 and served as President & CEO of SkinMedica until 2010. He continued to serve on the board until it was acquired by Allergan in 2012. He currently serves on the boards of Foamix Pharmaceuticals (NASD:FOMX), MDRejuvena and Clarify Medical. He is a member of the American Academy of Dermatology. He has completed executive programs at Harvard, Dartmouth, Stanford and Northwestern University and holds a B.A. degree in Business Administration from Drury University in Springfield, Missouri.

John T. Buhler

Mr. Buhler has been CEO/COO of three public and three private companies. He currently serves as Chief Executive Officer and President of Omniguide Holdings, Inc.

Mr. Buhler formerly served as CEO & President of RF Surgical Systems, President & COO of Natus Medical, CEO & President of SenoRx, and Ultrasonix Medical Corporation. He has over 30 years’ experience as a senior executive and business leader in medical technology companies such as GE Healthcare, and Diasonics VingMed Ultrasound, serving as Vice President and General Manager for both entities. At GE healthcare, Mr. Buhler headed up its global Performance Technologies division from 2001-2004. This position led commercial operations throughout Asia, delivering double digit revenue and margin growth annually.

Mr. Buhler has served as a Board Director for the following companies: GE-Wipro, Ultrasonix Medical Corporation, SenoRx Inc., Natus Medical, RF Surgical Systems, OmniGuide Holdings, Heart Force Medical, and Verrix.

Raymond Huggenberger

Mr. Huggenberger is a Director of Inogen, Inc. and served as its CEO from 2008-2017 and as its President from 2008-2016. Mr. Huggenberger led the company through a period of rapid revenue growth through direct-to-patient marketing, during which its share price increased.

He formerly served as President and COO and Group President of European Operations of Sunrise Medical Inc. He also previously served as President of Sunrise Medical Germany and as its Vice President of Marketing. Mr. Huggenberger also serves on the Board of Directors of Wellfount Corporation, Tactile Medical Systems and Sommetrics Inc. and is a member of the Technical Advisory Board of Arboretum Ventures LLP.

Mr. Huggenberger has over 20 years of deep experience in outpatient health care products and services, and in direct to patient and international sales and marketing.

George Mahaffey

Mr. Mahaffey is the President and CEO of Clarify Medical, and has over 30 years of pharmaceutical and biotechnology industry experience. In March 2011 he was named President and CEO of Lithera, Inc., later renamed Neothetics, a clinical stage special pharmaceutical aesthetics company.  While there he successfully completed an IPO in November 2014.  He previously served as CEO of Peplin, Inc. after the dermatology company was acquired by LEO Pharma A/S in 2009, where he played an instrumental role in the transaction. Prior to the acquisition, he served as Peplin’s Chief Commercial Officer and VP, Sales and Marketing. Mr. Mahaffey also served as Sr. VP, Sales and Marketing for Cotherix, Inc. where he led the corporate commercialization and successful launch of Ventavis® (iloprost), an orphan drug to treat Pulmonary Arterial Hypertension. He was heavily involved in the acquisition of CoTherix by Actelion Ltd. in 2007. Prior to CoTherix, Mr. Mahaffey worked at Scios, Inc. (acquired by Johnson & Johnson in 2003) where he led the launch of Natrecor® (nesiritide) to treat acutely decompensated congestive heart failure. Mr. Mahaffey also worked in various marketing functions at Neurex, Inc. (acquired by Elan Corp. in 1998). He began his pharmaceutical career at DuPont Pharmaceuticals where he held various sales and marketing positions. Mr. Mahaffey has a Chemical Engineering degree from the University of Delaware and an MBA from the University of South Florida.

Blog

Meet the College Senior Repigmenting Her Face with Clarify Medical’s Home Light Therapy

by Phototherapy, Vitiligo

Simone shows the pigment returning on her face. Left, Simone before the treatment. Right, Simone’s most recent picture after three weeks of using Clarify Medical’s Home Light Therapy System. These photos have not been retouched. Repost from livingdappled.com Thanks to Clarify Medical for sponsoring this post! Living Dappled did receive compensation for this post, but the….

News & Media

Contact Us.
We’re here to help.

Clarify Medical
401 W. A St. Suite 950
San Diego, CA 92101

Sales: +1 (877) 738-6041
Corporate: +1 (877) 520-5697
Fax: +1 (844) 562-6896

info@clarifymed.com

We are committed to providing innovative technology and support services for people with chronic skin conditions. We welcome your feedback and invite your questions.

Contact Form Inquire Reason: